Drug treatment of poststroke aphasia

Expert Review of Neurotherapeutics

Volumn 4, Issue 2, 2004, Pages 211-217

  Bakheit, A M O ^a,b  

^a Mount Gould Hospital   (United Kingdom)

^b PENINSULA MEDICAL SCHOOL   (United Kingdom)

Author keywords

Amphetamines; Aphasia; Bromocriptine; Drug therapy; Piracetam; Stroke

Indexed keywords

AMOBARBITAL; BROMOCRIPTINE; DEXAMPHETAMINE; DONEPEZIL; DOPAMINE; HALOPERIDOL; NORADRENALIN; PIRACETAM;

APHASIA; ATAXIC APHASIA; ATTENTION; CLINICAL TRIAL; CORTICAL SENSORY APHASIA; HUMAN; LEARNING; MEMORY; PROGNOSIS; READING; REVIEW; SIDE EFFECT; STROKE; VERBAL COMMUNICATION;

AMPHETAMINE; APHASIA; BROMOCRIPTINE; CEREBROVASCULAR ACCIDENT; HUMANS;

EID: 1542374112     PISSN: 14737175     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737175.4.2.211     Document Type: Review

References (46)

1. Kreisler A, Godefroy O, Delmaire C et al. The anatomy of aphasia revisited. Neurology 54, 1117-1123 (2000).
2. Stegmayer B, Asplund K, Wester PO. Trends in incidence, case-fatality rate and severity of stroke in northern Sweden, 1985-1991. Stroke 25, 1734-1745 (1994).
3. Kertesz A, McCabe P. Recovery patterns and prognosis in aphasia. Brain 100, 1-18 (1977).
4. Laska AC, Hellbolm A, Murray V, Kahan T, von Arbin M. Aphasia in acute stroke in relation to outcome. J. Int. Med. 249, 413-422 (2001).
5. Robinson RG, Bolduc PL, Price TR. Two-year longitudinal study of poststroke mood disorders: diagnosis and outcome at 1 and 2 years. Stroke 18, 837-843 (1987).
6. Astrom M, Adolfsson R Asplund K. Major depression in stroke patients. A 3-year longitudinal study. Stroke 24, 976-982 (1993).
7. Tennant A, Geddes JML, Fear J, Hillman M, Chamberlain MA. Outcome following stroke. Dis. Rehab. 19, 278-284 (1997).
8. Pulvermuller F, Neininger B, Elbert T et al. Constraint induced therapy of chronic aphasia after stroke. Stroke 32, 1621-1626 (2001).
9. Katz CR, Wertz RT. The efficacy of computer-provided reading treatment for chronic aphasic adults. J. Speech Language Hearing Res. 40, 493-407 (1997).
10. Aftonomos LB, Steele RD, Wertz RT. Promoting recovery in chronic aphasia with an interactive technology. Arch. Phys. Med. Rehab. 78, 841-846 (1997).
11. Code C. Multifactorial processes in recovery from aphasia: developing foundations for a multileveled framework. Brain Lang. 77, 25-44 (2001).
12. Lincoln NB, McGuirk E, Mulley GP, Lendrem W, Jones AC, Mitchell JA. Effectiveness of speech therapy for aphasia stroke patients: a randomised controlled trial. Lancet 1, 1197-1200 (1984).
13. Wertz RT, Weiss DG, Aren JL et al. Comparison of clinic, home and deferred language treatment for aphasia: a Veterans Administration co-operative study. Arch. Neurol. 43, 653-658 (1986).
14. Robey RR. A meta-analysis of clinical outcomes in the treatment of aphasia. J. Speech Lang. Hearing Res. 41, 172-187 (1998).
15. Feeney DM, Gonzalez A, Law WA. Amphetamine, haloperidol and experience interact to affect rate of recovery after motor cortex injury. Science 217, 855-857 (1982).
16. Goldstein LB, Miller GD, Cress MM, Tyson AG, Davis JN. Studies of an animal model for recovery of function after stroke. Ann. Neurol. 22, 159-160 (1988).
17. Hovda DA, Feeney DM. Amphetamine with experience promotes recovery of locomotor function after unilateral frontal cortex injury in the cat. Brain Res. 298, 358-361 (1984). Provides evidence that the combination of training with drug use (amphetamine) promotes neural plasticity in animal models of acute brain injury.
18. Feeney DM, Hovda DA. Reinstatement of binocular depth perception by amphetamine and visual experience after visual cortex ablation. Brain Res. 342, 352-356 (1985).
19. Feeney DM, Hovda DA. Amphetamine and apomorphine restore tactile placing after motor cortex injury in the cat. Psychopharmacology 79, 67-71 (1983).
20. Meyer JS, Stoica E, Pascu I, Shimazu K, Hartman A. Catecholamine concentrations in CSF and plasma of patients with cerebral infarction and haemorrhage. Brain 96, 277-288 (1973).
21. Porch B, Wyckes J, Feeney DM. Haloperidol, thiazides and some antihypertensives slow recovery from aphasia. Proc. Ann. Meet. Soc. Neuro. 52, (1985).
22. Cohen LG, Brasil-Neto JP, Pascual-Leone A, Hallett M. Plasticity of cortical motor output organisation following deafferentation, cerebral lesions and skill acquisition. Advan. Neurol. 63, 187-200 (1993).
23. Albert ML, Bachman DL, Morgan A Helm-Estabrooks N. Pharmacotherapy for aphasia. Neurology 38, 877-879 (1988).
24. Gupta SR, Mlcoch AG. Bromocriptine treatment of nonfluent aphasia. Arch Phys. Med. Rehab. 73, 373-376 (1992).
25. Raymer AM, Bandy D, Adair JC et al. Effects of bromocriptine in a patient with crossed nonfluent aphasia: a case report. Arch Phys. Med. Rehab. 82, 139-144 (2001).
26. Sabe L, Leiguarda R, Starkstein SE. An open-label trial of bromocriptine in nonfluent aphasia. Neurology 42, 1637-1638 (1992).
27. Gold M, VanDAm D, Silliman ER. An open-label trial of bromocriptine in nonfluent aphasia: a qualitative analysis of word storage and retrieval. Brain Lang. 74, 141-146 (2000).
28. Sabe L, Salvarezza F Cuerva AG, Leiguarda R, Starkstein S. A randomised, double-blind, placebo-controlled study of bromocriptine in nonfluent aphasia. Neurology 45, 2272-2274 (1995).
29. Gupta SR, Mlcoch AG, Scolaro C, Mortiz T. Bromocriptine treatment of nonfluent aphasia. Neurology 45, 2170-2173 (1995).
30. Bragoni M, Altieri M, Di Piero V, Padovani A, Mostardini C, Lenzi GL. Bromocriptine and speech therapy in nonfluent chronic aphasia after stroke. Neuro. Sci. 21, 19-22 (2000).
31. Rossillon D, Vanwyck R, Bayet B, Calteux N, De ConinckA. The action of piracetam in ischaemic flaps. Br. J. Plastic Surg. 40, 459-466 (1987).
32. Vernon MW, Sorkin EM. Piracetam - an overview of its pharmacological properties and a review of its therapeutic use in senile cognitive disorders. Drugs Ageing 1, 17-35 (1991).
33. Waegemans T, Wilsher CR, Danniau A et al. Clinical efficacy of piracetam: a meta-analysis. Dementia Geriatric Cog. Dis. 13, 217-224 (2002).
34. Enderby P, Broeckx J, Hospers W, Schildermans F, Debrendt W. Effect of piracetam on recovery and rehabilitation after stroke. A double-blind, placebo-controlled study. Clin. Neuropharmacol. 17, 320-331 (1994).
35. Huber W, Willmes K, Poeck K, Van Vleymen B, Deberdt WI. Piracetam as an adjuvant to language therapy for aphasia: randomised double-blind placebo-controlled pilot study. Arch Phys. Med. Rehab. 78, 245-250 (1997). Suggests that piracetam is useful in the treatment of aphasia when given together with conventional speech and language therapy.
36. Darley FL. The efficacy of language rehabilitation in aphasia. J. Speech Hearing Dis. 30, 3-22 (1972).
37. De Deyn P, De Reuck, Orgogozo JM, Vlietinck R, Deberdt W. Treatment of acute ischemic stroke with piracetam. Stroke 28, 2347-2352 (1997).
38. Orgogozo JM. Piracetam in the treatment of acute stroke. Pharmacopsychiatry 32(Suppl. 1), 25-32 (1999).
39. Wade DT. Measurement in Neurological Rehabilitation. Oxford University Press, Oxford, UK, 63-64 (1992).
40. Kessler J, Thiel A, Karbe H, Heiss WD. Piracetam improves activated blood flow and facilitates rehabilitation of poststroke aphasic patients. Stroke 31, 2112-2116 (2000). Demonstrates that piracetam improves cerebral blood flow in vivo in language areas. This observation suggests that rescue of the ischemic zone early after stroke may be responsible for the reported beneficial effects of this drug in aphasia.
41. Cao Y, Vikingstad EM, George KP, Johnson AF, Welch KMA. Cortical language activation in stroke patients recovering from aphasia with functional MRI. Stroke 30, 2331-2340 (1999).
42. Lee SM, Weisskopf MG, Ebner FF. Horizontal longterm potentiation of responses in rat somatosensory cortex. Brain Res. 554, 303-310 (1991).
43. Walker-Batson D, Curtis S, Natarajan R et al. A double-blind, placebo-controlled study of the use of amphetamine in the treatment of aphasia. Stroke 32, 2093-2098 (2001).
44. Berthier ML, Hinojosa J, Martin MC, Fernandez I. Open-label study of donepezil in chronic poststroke aphasia. Neurology 60, 1218-1219 (2003).
45. Greener J, Enderby P, Whurr R. Pharmacological treatment for aphasia following stroke. Cochrane Database Sys. Rev. CD000424 (2001).
46. Lazar RM, Marshall RS, Prell GD, Pile-Spellman J. The experience of Wernicke's aphasia. Neurology 55, 1222-1224 (2000). Challenges the traditional assumptions regarding the clinical features of receptive aphasia. If this observation is confirmed, it may have important implications for aphasia rehabilitation.